Olanzapine Pharmacokinetics: A Clinical Review of Current Insights and Remaining Questions

References

• Fan J, de Lannoy IAM. Pharmacokinetics. Biochem Pharmacol. 2014;87(1):93–120. doi:10.1016/j.bcp.2013.09.007
   PubMed Web of Science ®Google Scholar
• Mangoni AA, Jackson SH. Age‐related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6–14. doi:10.1046/j.1365-2125.2003.02007.x
   PubMed Web of Science ®Google Scholar
• Jovanović M, Vučićević K, Miljković B. Understanding variability in the pharmacokinetics of atypical antipsychotics–focus on clozapine, olanzapine and aripiprazole population models. Drug Metab Rev. 2020;52(1):1–8. doi:10.1080/03602532.2020.1717517
   PubMed Web of Science ®Google Scholar
• Correll CU, Kim E, Sliwa JK, et al. Pharmacokinetic characteristics of long-acting injectable antipsychotics for schizophrenia: an overview. CNS Drugs. 2021;35(1):39–59. doi:10.1007/s40263-020-00779-5
   PubMed Web of Science ®Google Scholar
• Olanzapine [package insert]. Indianapolis (IN): Eli Lilly and Company; 2009.
   Google Scholar
• Lybalvi [package insert]. Waltham (MA): Alkermes Inc; 2021.
   Google Scholar
• Ward K, Citrome L. The treatment of acute agitation associated with schizophrenia or bipolar disorder: investigational drugs in early stages of their clinical development, and their clinical context and potential place in therapy. Expert Opin Investi Drug. 2020;29(3):245–257. doi:10.1080/13543784.2020.1727884
   PubMed Web of Science ®Google Scholar
• Bahji A, Ermacora D, Stephenson C, Hawken ER, Vazquez G. Comparative efficacy and tolerability of pharmacological treatments for the treatment of acute bipolar depression: a systematic review and network meta-analysis. J Affect Disorder. 2020;269:154–184. doi:10.1016/j.jad.2020.03.030
   PubMed Web of Science ®Google Scholar
• Kishi T, Ikuta T, Matsuda Y, et al. Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials. Molecul psychiatr. 2022;27(2):1136–1144. doi:10.1038/s41380-021-01334-4
   PubMed Web of Science ®Google Scholar
• Nestsiarovich A, Gaudiot CE, Baldessarini RJ, Vieta E, Zhu Y, Tohen M. Preventing new episodes of bipolar disorder in adults: systematic review and meta-analysis of randomized controlled trials. Eur. Neuropsychopharmacol. 2022;54:75–89. doi:10.1016/j.euroneuro.2021.08.264
   PubMed Web of Science ®Google Scholar
• Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939–951. doi:10.1016/S0140-6736(19)31135-3
   PubMed Web of Science ®Google Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–962. doi:10.1016/S0140-6736(13)60733-3
   PubMed Web of Science ®Google Scholar
• Schneider-Thoma J, Chalkou K, Dörries C, et al. Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis. Lancet. 2022;399(10327):824–836. doi:10.1016/S0140-6736(21)01997-8
   PubMed Web of Science ®Google Scholar
• Pillinger T, McCutcheon RA, Vano L, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatr. 2020;7(1):64–77. doi:10.1016/S2215-0366(19)30416-X
   PubMed Web of Science ®Google Scholar
• Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):71–93. doi:10.1093/schbul/sbp116
   PubMed Web of Science ®Google Scholar
• Galletly C, Castle D, Dark F, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Austra N Z J Psychiatr. 2016;50(5):410–472. doi:10.1177/0004867416641195
   PubMed Web of Science ®Google Scholar
• Keating D, McWilliams S, Schneider I, et al. Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode. BMJ open. 2017;7(1):e013881. doi:10.1136/bmjopen-2016-013881
   PubMed Web of Science ®Google Scholar
• Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorder. 2018;20(2):97–170. doi:10.1111/bdi.12609
   PubMed Web of Science ®Google Scholar
• Faden J, Serdenes R, Citrome L. Olanzapine-samidorphan combination tablets for the treatment of schizophrenia and bipolar I disorder-what is it, and will it be used? Expert Rev Neurother. 2022;22(5):365–376. doi:10.1080/14737175.2022.2060742
   PubMed Web of Science ®Google Scholar
• Citrome L, McEvoy JP, Todtenkopf MS, McDonnell D, Weiden PJ. A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future. Neuropsychiatr Dis Treat. 2019;5:2559–2569. doi:10.2147/NDT.S209284
   Google Scholar
• Cong L, Wan Z, Li P, et al. Metabolic, genetic, and pharmacokinetic parameters for the prediction of olanzapine efficacy. Eur J Pharm Sci. 2022;177:106277. doi:10.1016/j.ejps.2022.106277
   PubMed Web of Science ®Google Scholar
• Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine: pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999;37(3):177–193. doi:10.2165/00003088-199937030-00001
   PubMed Web of Science ®Google Scholar
• Mao JH, Han L, Liu XQ, Jiao Z. Significant predictors for olanzapine pharmacokinetics: a systematic review of population pharmacokinetic studies. Expert Rev Clin Pharmacol. 2023;16(6):575–588. doi:10.1080/17512433.2023.2219055
   PubMed Web of Science ®Google Scholar
• Bishara D, Olofinjana O, Sparshatt A, Kapur S, Taylor D, Patel MX. Olanzapine: a systematic review and meta-regression of the relationships between dose, plasma concentration, receptor occupancy, and response. J Clin Psychopharmacol. 2013;33(3):329–335. doi:10.1097/JCP.0b013e31828b28d5
   PubMed Web of Science ®Google Scholar
• Kapur S, Zipursky RB, Remington G, et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry. 1998;155(7):921–928. doi:10.1176/ajp.155.7.921
   PubMed Web of Science ®Google Scholar
• Bymaster FP, Rasmussen K, Calligaro DO, et al. In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug. J Clin Psychiatr. 1997;58(10):28–36.
   PubMedGoogle Scholar
• Vinish M, Elnabawi A, Milstein JA, et al. Olanzapine treatment of adolescent rats alters adult reward behaviour and nucleus accumbens function. Int J Neuropsychopharmacol. 2013;16(7):1599–1609. doi:10.1017/S1461145712001642
   PubMed Web of Science ®Google Scholar
• Mauri MC, Paletta S, Maffini M, et al. Clinical pharmacology of atypical antipsychotics: an update. EXCLI J. 2014;13:1163.
   PubMed Web of Science ®Google Scholar
• Erickson KK, Zhu J, Lazarus P. Olanzapine metabolism and the significance of the UGT1A448V and UGT2B1067Y variants. Pharmacogene Geno. 2011;21(9):539. doi:10.1097/FPC.0b013e328348c76b
   PubMed Web of Science ®Google Scholar
• Calligaro DO, Fairhurst J, Hotten TM, Moore NA, Tupper DE. The synthesis and biological activity of some known and putative metabolites of the atypical antipsychotic agent olanzapine (LY170053). Bioorg Med Chem Lett. 1997;7(1):25–30. doi:10.1016/S0960-894X(96)00567-7
   Web of Science ®Google Scholar
• Kassahun K, Mattiuz E, Nyhart E, et al. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab Dispos. 1997;25(1):81–93.
   PubMed Web of Science ®Google Scholar
• Czerwensky F, Leucht S, Steimer W. CYP1A2* 1D and* 1F polymorphisms have a significant impact on olanzapine serum concentrations. Ther Drug Monit. 2015;37(2):152–160. doi:10.1097/FTD.0000000000000119
   PubMed Web of Science ®Google Scholar
• Söderberg MM, Dahl ML. Pharmacogenetics of olanzapine metabolism. Pharmacogenomics. 2013;14(11):1319–1336. doi:10.2217/pgs.13.120
   PubMed Web of Science ®Google Scholar
• Soria-Chacartegui P, Villapalos-García G, Zubiaur P, Abad-Santos F, Koller D. Genetic polymorphisms associated with the pharmacokinetics, pharmacodynamics and adverse effects of olanzapine, aripiprazole and risperidone. Front Pharmacol. 2021;12:711940. doi:10.3389/fphar.2021.711940
   PubMed Web of Science ®Google Scholar
• Hägg S, Spigset O, Lakso H, Dahlqvist R. Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes. Eur J Clin pharmacol. 2001;57(6–7):493–497. doi:10.1007/s002280100343
   PubMed Web of Science ®Google Scholar
• Cabaleiro T, López‐Rodríguez R, Ochoa D, Román M, Novalbos J, Abad‐Santos F. Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects. Human Psychopharmacol. 2013;28(3):205–214. doi:10.1002/hup.2308
   PubMed Web of Science ®Google Scholar
• Zubiaur P, Soria-Chacartegui P, Villapalos-García G, Gordillo-Perdomo JJ, Abad-Santos F. The pharmacogenetics of treatment with olanzapine. Pharmacogenomics. 2021;22(14):939–958. doi:10.2217/pgs-2021-0051
   PubMed Web of Science ®Google Scholar
• Schmitt U, Kirschbaum KM, Poller B, et al. In vitro P-glycoprotein efflux inhibition by atypical antipsychotics is in vivo nicely reflected by pharmacodynamic but less by pharmacokinetic changes. Pharmacol Biochem Behav. 2012;102(2):312–320. doi:10.1016/j.pbb.2012.04.002
   PubMed Web of Science ®Google Scholar
• Koller D, Almenara S, Mejía G, et al. Metabolic effects of aripiprazole and olanzapine multiple-dose treatment in a randomised crossover clinical trial in healthy volunteers: association with pharmacogenetics. Adv Ther. 2021;38(2):1035–1054. doi:10.1007/s12325-020-01566-w
   PubMed Web of Science ®Google Scholar
• Markowitz JS, DeVane CL, Malcolm RJ, et al. Pharmacokinetics of olanzapine after single‐dose oral administration of standard tablet versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers. J Clin Pharmacol. 2006;46(2):164–171. doi:10.1177/0091270005283839
   PubMed Web of Science ®Google Scholar
• Battaglia J. Intramuscular olanzapine: treating acute agitation in psychosis and bipolar mania. Curr Psychiatry. 2004;3:76–78.
   Google Scholar
• Heres S, Kraemer S, Bergstrom RF, Detke HC. Pharmacokinetics of olanzapine long-acting injection: the clinical perspective. Int Clin Psychopharmacol. 2014;29(6):299. doi:10.1097/YIC.0000000000000040
   PubMed Web of Science ®Google Scholar
• Lorenzo MP, Burgess J, Darko W. Intravenous olanzapine in a critically ill patient: an evolving route of administration. Hospital Pharm. 2020;55(2):108. doi:10.1177/0018578718823484
   PubMed Web of Science ®Google Scholar
• fda.gov, A. ZYPREXA (olanzapine) Label; 2015. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020592s042s043,021086s022s023,021253s026lbl.pdf. Accessed December 1 2023.
   Google Scholar
• fda.gov, A. ZYPREXA RELPREVV (olanzapine) For Extended Release; 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022173s027lbl.pdf. Accessed December 1 2023.
   Google Scholar
• Kooij KL, Luijendijk MC, Drost L, Platenburg G, van Elburg A, Adan RA. Intranasal administration of olanzapine has beneficial outcome in a rat activity-based anorexia model. Eur Neuropsychopharmacol. 2023;71:65–74. doi:10.1016/j.euroneuro.2023.03.008
   PubMed Web of Science ®Google Scholar
• Cole JB, Moore JC, Dolan BJ, et al. A prospective observational study of patients receiving intravenous and intramuscular olanzapine in the emergency department. Ann Emergency Med. 2017;69(3):327–336. doi:10.1016/j.annemergmed.2016.08.008
   PubMed Web of Science ®Google Scholar
• Symbyax [package insert]. Indianapolis (IN): Eli Lilly and Company; 2003.
   Google Scholar
• Gossen D, De Suray JM, Vandenhende F, Onkelinx C, Gangji D. Influence of fluoxetine on olanzapine pharmacokinetics. Aaps Pharmsci. 2002;4(2):56–61. doi:10.1208/ps040209
   Google Scholar
• Nemeroff CB. Dosing the antipsychotic medication olanzapine. J Clin Psychiatr. 1997;58(10):45–49.
   PubMedGoogle Scholar
• Takeuchi H, Fervaha G, Lee J, Agid O, Remington G. Effectiveness of different dosing regimens of risperidone and olanzapine in schizophrenia. Eur Neuropsychopharmacol. 2015;25(3):295–302. doi:10.1016/j.euroneuro.2014.12.008
   PubMed Web of Science ®Google Scholar
• Citrome L, Kantrowitz J. Olanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction? Expert Rev Neurother. 2009;9(7):1045–1058. doi:10.1586/ern.09.54
   PubMed Web of Science ®Google Scholar
• Beasley CM, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996;14(2):111–123. doi:10.1016/0893-133X(95)00069-P
   PubMed Web of Science ®Google Scholar
• Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Cambridge university press; 2021.
   Google Scholar
• Reich J. Use of high-dose olanzapine in refractory psychosis. Am J Psychiatry. 1999;156(4):661. doi:10.1176/ajp.156.4.661
   PubMed Web of Science ®Google Scholar
• Kinon BJ, Volavka J, Stauffer V, et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J Clin Psychopharmacol. 2008;28(4):392–400. doi:10.1097/JCP.0b013e31817e63a5
   PubMed Web of Science ®Google Scholar
• Mitchell M, Riesenberg R, Bari MA, et al. A double-blind, randomized trial to evaluate the pharmacokinetics and tolerability of 30 or 40 mg/d oral olanzapine relative to 20 mg/d oral olanzapine in stable psychiatric subjects. Clin Ther. 2006;28(6):881–892. doi:10.1016/j.clinthera.2006.06.008
   PubMed Web of Science ®Google Scholar
• Morgan M, Hackett LP, Isbister GK. Olanzapine overdose: a series of analytically confirmed cases. Int Clin Psychopharmacol. 2007;22(3):183–186. doi:10.1097/YIC.0b013e32805aedf5
   PubMed Web of Science ®Google Scholar
• Gex-Fabry M, Balant-Gorgia AE, Balant LP. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther Drug Monit. 2003;25(1):46–53. doi:10.1097/00007691-200302000-00007
   PubMed Web of Science ®Google Scholar
• Hiemke C, Baumann P, Bergemann N, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry. 2011;21(06):195–235.
   Google Scholar
• Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(01/02):9–62. doi:10.1055/s-0043-116492
   PubMed Web of Science ®Google Scholar
• der AGNP Federführend TA, Rao ML, Hiemke C, Grasmäder K, Baumann P. Olanzapin: pharmakologie, pharmakokinetik und therapeutisches drug monitoring. Fortsch Der Neurol Psychiatr. 2001;69(11):510–517. doi:10.1055/s-2001-18381
   PubMedGoogle Scholar
• Stillhart C, Vučićević K, Augustijns P, et al. Impact of gastrointestinal physiology on drug absorption in special populations––An UNGAP review. Eur J Pharm Sci. 2020;147:105280. doi:10.1016/j.ejps.2020.105280
   PubMed Web of Science ®Google Scholar
• Seaman JS, Bowers SP, Dixon P, Schindler L. Dissolution of common psychiatric medications in a Roux-en-Y gastric bypass model. Psychosomatics. 2005;46(3):250–253. doi:10.1176/appi.psy.46.3.250
   PubMed Web of Science ®Google Scholar
• Zheng L, Yang H, Dallmann A, Jiang X, Wang L, Hu W. Physiologically based pharmacokinetic modeling in pregnant women suggests minor decrease in maternal exposure to olanzapine. Front Pharmacol. 2022;12:793346. doi:10.3389/fphar.2021.793346
   PubMed Web of Science ®Google Scholar
• Withers N. The Liver Impaired Patient. In: Handbook of Consultation Liaison Psychiatry. New York: Springer; 2008:248–269.
   Google Scholar
• Telles-Correia D, Barbosa A, Cortez-Pinto H, Campos C, Rocha NB, Machado S. Psychotropic drugs and liver disease: a critical review of pharmacokinetics and liver toxicity. World J Gastroint Pharmacol Ther. 2017;8(1):26. doi:10.4292/wjgpt.v8.i1.26
   PubMedGoogle Scholar
• Sun L, Yagoda S, Du Y, von Moltke L. Effect of hepatic and renal impairment on the pharmacokinetics of olanzapine and samidorphan given in combination as a bilayer tablet. Drug Design Devel Ther. 2019;22:2941–2955. doi:10.2147/DDDT.S205000
   Google Scholar
• Cussotto S, Walsh J, Golubeva AV, et al. The gut microbiome influences the bioavailability of olanzapine in rats. EBioMedicine. 2021;2021:66.
   Google Scholar
• Kansagra A, Patel S, Wilcox SR. Prolonged hypothermia due to olanzapine in the setting of renal failure: a case report and review of the literature. Ther Adv Psychopharmacol. 2013;3(6):335–339. doi:10.1177/2045125313490304
   PubMedGoogle Scholar
• Marder SR, Sorsaburu S, Dunayevich E, et al. Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation. J Clin Psychiatr. 2010;71(4):2392. doi:10.4088/JCP.08m04411gry
   Web of Science ®Google Scholar
• Williams AM. Coadministration of intramuscular olanzapine and benzodiazepines in agitated patients with mental illness. Mental Health Clinician. 2018;8(5):208–213. doi:10.9740/mhc.2018.09.208
   PubMedGoogle Scholar
• Olanzapine [Package Insert]. Utrecht, The Netherlands: Lilly, SA; 2006.
   Google Scholar
• Wilson MP, Chen N, Vilke GM, Castillo EM, MacDonald KS, Minassian A. Olanzapine in ED patients: differential effects on oxygenation in patients with alcohol intoxication. Am J Emergency Med. 2012;30(7):1196–1201. doi:10.1016/j.ajem.2012.03.013
   PubMed Web of Science ®Google Scholar
• Anderson GD, Chan LN. Pharmacokinetic drug interactions with tobacco, cannabinoids and smoking cessation products. Clin Pharmacokinet. 2016;55(11):1353–1368. doi:10.1007/s40262-016-0400-9
   PubMed Web of Science ®Google Scholar
• Chiu CC, Lane HY, Huang MC, et al. Dose‐dependent alternations in the pharmacokinetics of olanzapine during coadministration of fluvoxamine in patients with schizophrenia. J Clin Pharmacol. 2004;44(12):1385–1390. doi:10.1177/0091270004270291
   PubMed Web of Science ®Google Scholar
• Lucas RA, Gilfillan DJ, Bergstrom RF. A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism. Eur J Clin pharmacol. 1998;54(8):639–643. doi:10.1007/s002280050527
   PubMed Web of Science ®Google Scholar
• Kasper S. Risperidone and olanzapine: optimal dosing for efficacy and tolerability in patients with schizophrenia. Int Clin Psychopharmacol. 1998;13(6):253–262. doi:10.1097/00004850-199811000-00003
   PubMed Web of Science ®Google Scholar
• Solmi M, Murru A, Pacchiarotti I, et al. Safety, tolerability, and risks associated with first-and second-generation antipsychotics: a state-of-the-art clinical review. Thera Clin Risk Manage. 2017;29:757–777. doi:10.2147/TCRM.S117321
   Google Scholar
• Compton MT, Miller AH. Antipsychotic-induced hyperprolactinemia and sexual dysfunction. Psychopharmacol Bull. 2002;36(1):143–164.
   PubMedGoogle Scholar
• Hu KF, Chou YH, Wen YH, et al. Antipsychotic medications and dental caries in newly diagnosed schizophrenia: a nationwide cohort study. Psychiatr Res. 2016;245:45–50. doi:10.1016/j.psychres.2016.07.047
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Lieberman JA, Perkins DO, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007;164(7):1050–1060. doi:10.1176/ajp.2007.164.7.1050
   PubMed Web of Science ®Google Scholar
• Detke HC, McDonnell DP, Brunner E, et al. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases. BMC psychiatr. 2010;10(1):1. doi:10.1186/1471-244X-10-43
   PubMedGoogle Scholar
• Seebaluck J, Downes MA, Brown J, Harris K, Isoardi KZ, Chan BS. Case series profile of olanzapine post‐injection delirium/sedation syndrome. Br J Clin Pharmacol. 2023;89(2):903–907. doi:10.1111/bcp.15588
   PubMed Web of Science ®Google Scholar
• Bushe CJ, Falk D, Anand E, et al. Olanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice. BMC psychiatr. 2015;15(1):1–8. doi:10.1186/s12888-015-0450-9
   PubMedGoogle Scholar
• Łukasik‐głębocka M, Sommerfeld K, Teżyk A, Panieński P, Żaba C, Zielińska‐Psuja B. Post‐injection delirium/sedation syndrome after olanzapine long‐acting intramuscular injection–who is at risk? Basic Clin Physiol Pharmacol. 2015;117(3):213–214. doi:10.1111/bcpt.12394
   Google Scholar
• Meyers KJ, Upadhyaya HP, Landry JL, et al. Postinjection delirium/sedation syndrome in patients with schizophrenia receiving olanzapine long-acting injection: results from a large observational study. BJPsych Open. 2017;3(4):186–192. doi:10.1192/bjpo.bp.116.004382
   PubMed Web of Science ®Google Scholar
• McDonnell DP, Detke HC, Bergstrom RF, et al. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism. BMC psychiatr. 2010;10(1):1. doi:10.1186/1471-244X-10-45
   PubMedGoogle Scholar
• Morissette P, Hreiche R, Mallet L, Vo D, Knaus EE, Turgeon J. Olanzapine prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. J Psychopharmacol. 2007;21(7):735–741. doi:10.1177/0269881106072669
   PubMed Web of Science ®Google Scholar
• Ciszowski K, Sein Anand J. Zaburzenia elektrokardiograficzne w ostrych zatruciach olanzapiną. Przeglad Lekarski. 2011;68:8.
   Google Scholar
• Choure BK, Gosavi D, Nanotkar S. Comparative cardiovascular safety of risperidone and olanzapine, based on electrocardiographic parameters and blood pressure: a prospective open label observational study. Indian J Pharmacol. 2014;46(5):493. doi:10.4103/0253-7613.140579
   PubMed Web of Science ®Google Scholar
• Hofmann MS, Overman MJ, Nates JL. Acute benzodiazepine toxicity exacerbated by concomitant oral olanzapine. J Community Support Oncol. 2016;14(4):178–179. doi:10.12788/jcso.0187
   Google Scholar
• Mouallem M, Wolf I. Olanzapine-induced respiratory failure. Am J Ger Psychiatr. 2001;9(3):304–305. doi:10.1097/00019442-200108000-00016
   PubMed Web of Science ®Google Scholar
• Mehta S, Pulungan Z, Jones BT, Teigland C. Comparative safety of atypical antipsychotics and the risk of pneumonia in the elderly. Pharmacoepidemiol Drug Saf. 2015;24(12):1271–1280. doi:10.1002/pds.3882
   PubMed Web of Science ®Google Scholar
• Dzahini O, Singh N, Taylor D, Haddad PM. Antipsychotic drug use and pneumonia: systematic review and meta-analysis. J Psychopharmacol. 2018;32(11):1167–1181. doi:10.1177/0269881118795333
   PubMed Web of Science ®Google Scholar
• Martel ML, Klein LR, Rivard RL, Cole JB, Heard K. A large retrospective cohort of patients receiving intravenous olanzapine in the emergency department. Aca Emer Med. 2016;23(1):29–35. doi:10.1111/acem.12842
   PubMed Web of Science ®Google Scholar
• Tsai YV, Fawzy JH, Durkin JB, Then JE, McGinnis CB. Off-label use of intravenous olanzapine for agitation after neurologic injury. Hospital Pharm. 2021;56(6):697–701. doi:10.1177/0018578720946767
   PubMed Web of Science ®Google Scholar
• Weiss U, Marksteiner J, Kemmler G, Saria A, Aichhorn W. Effects of age and sex on olanzapine plasma concentrations. J Clin Psychopharmacol. 2005;25(6):570–574. doi:10.1097/01.jcp.0000185427.08268.db
   PubMed Web of Science ®Google Scholar
• de Lima Moreira F, de Lima Benzi JR, Pinto L, de Lucca Thomaz M, Duarte G, Lanchote VL. Optimizing therapeutic drug monitoring in pregnant women: a critical literature review. Ther Drug Monit. 2023;45(2):159–172. doi:10.1097/FTD.0000000000001039
   PubMed Web of Science ®Google Scholar
• Park Y, Hernandez-Diaz S, Bateman BT, et al. Continuation of atypical antipsychotic medication during early pregnancy and the risk of gestational diabetes. Am J Psychiatry. 2018;175(6):564–574. doi:10.1176/appi.ajp.2018.17040393
   PubMed Web of Science ®Google Scholar
• Newport DJ, Calamaras MR, DeVane CL, et al. Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. Am J Psychiatry. 2007;164(8):1214–1220. doi:10.1176/appi.ajp.2007.06111886
   PubMed Web of Science ®Google Scholar
• Ellfolk M, Leinonen MK, Gissler M, Kiuru-Kuhlefelt S, Saastamoinen L, Malm H. Second-generation antipsychotic use during pregnancy and risk of congenital malformations. Eur J Clin Pharmacol. 2021;77(11):1737–1745. doi:10.1007/s00228-021-03169-y
   PubMed Web of Science ®Google Scholar
• Fortinguerra F, Clavenna A, Bonati M. Psychotropic drug use during breastfeeding: a review of the evidence. Pediatrics. 2009;124(4):e547–56. doi:10.1542/peds.2009-0326
   PubMed Web of Science ®Google Scholar
• Uguz F. Second-generation antipsychotics during the lactation period: a comparative systematic review on infant safety. J Clin Psychopharmacol. 2016;36(3):244–252. doi:10.1097/JCP.0000000000000491
   PubMed Web of Science ®Google Scholar
• Maharaj AR, Wu H, Zimmerman KO, et al. Population pharmacokinetics of olanzapine in children. Br J Clin Pharmacol. 2021;87(2):542–554. doi:10.1111/bcp.14414
   PubMed Web of Science ®Google Scholar
• Liu XI, Schuette P, Burckart GJ, et al. A comparison of pediatric and adult safety studies for antipsychotic and antidepressant drugs submitted to the United States Food and Drug Administration. J Pediatr. 2019;208:236–242. doi:10.1016/j.jpeds.2018.12.033
   PubMed Web of Science ®Google Scholar
• Skogh E, Reis M, Dahl ML, Lundmark J, Bengtsson F. Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting. Ther Drug Monit. 2002;24(4):518–526. doi:10.1097/00007691-200208000-00010
   PubMed Web of Science ®Google Scholar